- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Aclarion, Inc.: Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data | 30 | GlobeNewswire (Europe) | Northwestern and Scripps Health join two previously announced sites in achieving this critical patient enrollment milestone Seven leading U.S. spine centers have now completed the regulatory and operational... ► Artikel lesen | |
| ACLARION Aktie jetzt für 0€ handeln | |||||
| 04.12.25 | Aclarion-Aktie steigt nach Vorstellung von Wirbelsäulen-Technologie in Fachjournal | 2 | Investing.com Deutsch | ||
| 04.12.25 | Aclarion's Nociscan featured in special pain issue of spine journal | 1 | Investing.com | ||
| 04.12.25 | Aclarion, Inc.: Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS) | 1 | GlobeNewswire (USA) | ||
| 12.11.25 | Aclarion: Interview With CEO Brent Ness About The Digital Health Company Addressing A Worldwide Epidemic | 4 | pulse2.com | ||
| 12.11.25 | Aclarion, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11.25 | Aclarion appoints first UK commercial director as insurance coverage expands | 1 | Investing.com | ||
| 05.11.25 | Aclarion, Inc.: Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion | 2 | GlobeNewswire (USA) | ||
| 22.10.25 | Aclarion, Inc.: Aclarion Wins "Rising Star" at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH | 1 | GlobeNewswire (USA) | ||
| 14.10.25 | Aclarion reports 89% increase in Nociscan scan volumes in Q3 | 1 | Investing.com | ||
| 14.10.25 | Aclarion, Inc.: Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst | 190 | GlobeNewswire (Europe) | Debt-free balance sheet with $13.3 million in cash as of today ($15.11 per share fully diluted) providing strategic flexibility for continued commercial growth Nociscan scan volumes increase +89%... ► Artikel lesen | |
| 14.10.25 | Aclarion, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.10.25 | Aclarion Stock Rises 32% After Global Pain Conference Presentation | 1 | RTTNews | ||
| 13.10.25 | Teilnahme an Fachkonferenz beflügelt Aclarion-Aktie | 1 | Investing.com Deutsch | ||
| 13.10.25 | Aclarion stock soars after participation in international pain meeting | 2 | Investing.com | ||
| 13.10.25 | XFRA MISTRADE ANTRAG IN ISIN US6551874091 WURDE ABGELEHNT | 238 | Xetra Newsboard | Der Mistrade-Antrag wurde abgelehnt. Folgende Geschaefte in der ISIN US6551874091, Wertpapier-Name: ACLARION NEW DL-,00001, werden nicht aufgehoben:Datum Zeit Volumen Preis13.10.2025 10:01:46 400 8,8 ► Artikel lesen | |
| 13.10.25 | XFRA MISTRADE ANTRAG IN ISIN US6551874091 WIRD GEPRUEFT | 212 | Xetra Newsboard | Fuer folgende Geschaefte in der ISIN US6551874091, Wertpapier-Name: ACLARION NEW DL-,00001, wird ein Mistrade-Antrag geprueft:Datum Zeit Volumen Preis13.10.2025 10:01:46 400 8.8Fair Value lt. Antragsteller:... ► Artikel lesen | |
| 09.10.25 | Aclarion to Present at the LD Micro Main Event XIX | 286 | Newsfile | Broomfield, Colorado--(Newsfile Corp. - October 9, 2025) - Aclarion, Inc. (NASDAQ: ACON) (NASDAQ: ACONW) ("Aclarion" or the "Company"), a healthcare technology company that is leveraging biomarkers... ► Artikel lesen | |
| 07.10.25 | Aclarion, Inc.: Aclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH | 1 | GlobeNewswire (USA) | ||
| 01.10.25 | Aclarion, Inc.: Aclarion Presents at LSI Europe '25 Highlighting Nociscan Technology and Key Value Drivers | 2 | GlobeNewswire (USA) |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| UNITEDHEALTH | 299,40 | +2,60 % | ROUNDUP/Aktien New York: Kaum verändert am vorletzten Handelstag des Jahres | NEW YORK (dpa-AFX) - Bei den wichtigsten US-Aktienindizes hat sich am Dienstag am vorletzten Handelstag des Jahres wenig getan. Der Dow Jones Industrial sank im frühen Handel um 0,08 Prozent auf 48.423... ► Artikel lesen | |
| INTUITIVE SURGICAL | 507,00 | +4,94 % | $100 Invested In Intuitive Surgical 20 Years Ago Would Be Worth This Much Today | ||
| THERMO FISHER | 533,30 | +2,30 % | BofA Raises Thermo Fisher (TMO) Target as Biopharma Recovery Comes Into View | ||
| ROKU | 97,01 | -0,84 % | Roku Becomes First Major Streamer To Use ISpot's Outcomes-Based Metric In Bid To Improve Ad Targeting | ||
| ATOSSA THERAPEUTICS | 0,569 | +7,16 % | Atossa Therapeutics Inc: Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer | SEATTLE, Jan. 6, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing innovative medicines for unmet... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update | -- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter --
-- Delivered $1.0 Million of Operating Income in Q3 2025 --
SAN DIEGO... ► Artikel lesen | |
| CENTENE | 39,065 | +2,48 % | Centene Jumps 16.3% in 3 Months: A Comeback or Calm Before the Storm? | ||
| QUIDELORTHO | 27,400 | +6,20 % | QuidelOrtho Corporation: QuidelOrtho Reports Third Quarter 2025 Financial Results | ? Total revenue of $700 million; excluding COVID-19 and Donor Screening, revenue grew mid-single digits, demonstrating solid underlying growth and momentum ? ... ► Artikel lesen | |
| VERU | 2,340 | +1,30 % | Veru Inc.: Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress | -- Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in combination with GLP-1 RA -- -- Incremental weight loss is an... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027 | All-stock acquisition includes clinical-stage CD19/BCMA Dual-CAR T programAcquisition will expand existing advanced clinical-stage pipeline of amezalpat (PPAR- Antagonist, Phase 3-ready) and TPST-1495... ► Artikel lesen | |
| NANO-X IMAGING | 3,025 | +0,33 % | NANO-X IMAGING LTD: Nanox Engages with Althea France to Accelerate European Commercialization of Nanox.ARC System | Althea France, part of one of Europe's largest independent medical technology services providers, to distribute CE-marked Nanox.ARC system across French healthcare sector Partnership represents Nanox's... ► Artikel lesen | |
| FULGENT GENETICS | 21,800 | 0,00 % | FLGT to Acquire Bako & StrataDx Assets to Expand Pathology Platform | ||
| LANTHEUS | 58,90 | +0,07 % | Lantheus Holdings, Inc.: Lantheus Announces Closing of SPECT Business Sale to SHINE Technologies | BEDFORD, Mass., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 2,420 | +4,31 % | Perspective Therapeutics, Inc.: Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results | Updated interim results from the Company's [212Pb]VMT-a-NET Phase 1/2a study supporting the therapy's compelling overall clinical profile at the 5 mCi dose were presented at the ESMO Congress 2025... ► Artikel lesen | |
| AMN HEALTHCARE SERVICES | 12,400 | +3,33 % | AMN Healthcare Services Inc: AMN Healthcare Announces Third Quarter 2025 Results | Quarterly revenue of $634 million and adjusted EBITDA of $58 million; GAAP income of $0.76/share and adjusted EPS of $0.39 DALLAS, Nov. 06, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE:... ► Artikel lesen |
ACLARION INC gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 4,210 Euro und damit +3,69 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACLARION INC finden Sie auf Wallstreet Online.